RHYTHM™ BIOSCIENCES

2019 ANNUAL REPORT

RHYTHM BIOSCIENCES LIMITED

ACN 619 459 335

COLORECTAL CANCER IS A SIGNIFICANT GLOBAL HEALTH RISK

EARLY DETECTION CAN INCREASE CURE RATES TO 90%

CONTENTS

RHYTHM BIOSCIENCES IS HITTING ITS MILESTONES AND REMAINS ON TRACK

Solid cash position
$4.7M
in bank at
30 June 2019

Product development and optimisation
on track

Clinical trial
Study 7
commenced with four sites appointed and recruiting

Regulatory submissions to
TGA & CE Mark
on track for FY21

Strong
management and Board

Secure
global patent
position

Reagent development kit in
advanced stage

Rhythm Biosciences Snapshot

Rhythm Biosciences Limited (ASX:RHY) is committed to developing and commercialising medical diagnostics technology for sale to national and international markets. In the short term Rhythm is focused on improving colorectal cancer survival rates through early diagnosis. Rhythm has one wholly owned subsidiary, Vision Tech Bio Pty Ltd, which owns the colorectal diagnostic technology and is advancing it to clinical and commercial applications.

Rhythm believes that a new simple blood test for colorectal cancer, whether used as a first-step screening test or in the triage of persons with a positive FIT result before colonoscopy, will help reduce morbidity, mortality and healthcare costs associated with colorectal cancer.

Rhythm Biosciences	Initial Proposed Product	Aim
An Australian medical diagnostics technology company	***ColoSTAT® — a simple, low cost and accurate blood test for the early detection of colorectal cancer***	***To reduce the impact of colorectal cancer globally through improved diagnosis***

Path to Commercialisation

13 years of research has been devoted to developing the ColoSTAT® technology by CSIRO, Australia's premier research body, prior to reaching Rhythm hands. Rhythm is using its product development and commercialisation expertise to transform this potentially life-saving technology from the research lab through the development process and then into the market as an in vitro diagnostic (IVD).

RHYTHM BIOSCIENCES SIMPLE, ACCURATE AND LOW COST BLOOD TEST WILL FILL A UNIQUE SPACE IN THE MASS SCREENING MARKET

Research and Development (case /control studies for over 13 years)

Reagent Development

IVD Kit Development and Production Transfer

Clinical Trial (Study 7)

Regulatory Submissions (Europe, Australia and the USA)

Market Entry Europe, Australia, USA + Others

COLORECTAL CANCER IS A SIGNIFICANT GLOBAL HEALTH RISK

Colorectal cancer is currently the 2nd largest cause of cancer related deaths globally. If detected early, cure rates can be as high as 90%

The risk of developing colorectal cancer increases dramatically above the age of 50. In countries such as Australia, UK, US and much of the Europe, colorectal cancer screening is recommended for all 50-74 year-olds, although in most of this elevated-risk population the majority remains under-screened. Colonoscopies, the most reliable diagnostic test for colorectal cancer, are invasive and expensive, while faecal tests suffer from low take-up rates with many in the target population having an aversion to handling their own stool, among other reasons.

Rhythm is striving to address this market opportunity with its in-development screening product ColoSTAT®, a simple, low cost, patient-friendly and accurate blood test for the early detection of colorectal cancer.

Colorectal Cancer is the

2nd most prevalent cancer

globally

Elevated risk people

remain under-screened

as current tests can be either off-putting or expensive

ColoSTAT® — a simple, low cost blood test for the

accurate & early detection of

colorectal cancer

NEW CASES AND DEATHS FROM COLORECTAL CANCER GLOBALLY

Number of colorectal cancer deaths

Global: over 850,000 deaths each year, with 1.8M new cases diagnosed annually

2nd largest cause of cancer death

United States

51,000

Europe

177,400

Australia

5,375

2nd most prevalent cancer

Source: International Agency for Research on Canercl www.gco.iarc.fr/today/fact-sheets-cancers

EARLY DETECTION IS THE KEY TO SURVIVAL

Description of colorectal cancer by stage and associated survival rates

Stage	Description	5-year % survival rate	Treatment
0	Abnormal cells are found in the epithelium (mucosal layer) lining the bowel wall, most often outgrowths (adenomas or polyps). These abnormal cells may become cancer and spread.	>96%	Typically, surgery to remove the adenoma or local excision through a colonoscope. Removing part of the colon (partial colectomy) is occasionally needed if a tumour is larger.
I	Tumour has invaded beyond the epithelium of bowel into the muscle layers below but has not spread past the bowel wall.	93%	Cancers of this stage require removal of the affected section of the large bowel and sometimes lymph node clearance but typically no additional treatment is necessary.
II	Cancer has grown through the muscle layer of the bowel and invaded nearby tissue, but has not spread to the lymph nodes	82%	Partial colectomy along with dissection of nearby lymph nodes may be the only treatment needed. Adjuvant chemotherapy may also be required.
III	Cancer has spread to the nearby lymph nodes but not to other parts of the body	59%	Partial colectomy along with dissection of nearby lymph nodes, along with adjuvant chemotherapy. If rectal, radiation therapy and/or chemo may be options for people not healthy enough for surgery.
IV	Metastatic bowel cancer where it has spread beyond the colon and rectum to other organs such as the liver or lung.	8%	Neoadjuvant chemotherapy to reduce tumour size, surgery and/or tumour stenting. Additional therapies also needed as well as radiation therapy and still only an 8% chance of survival.

Governments currently fund screening for 50-74 year olds

However, there are currently over

132,628,000 MILLION PEOPLE

who fall within the at-risk age not being screened each year

GLOBAL SCREENING OF 50-74 YEAR OLDS

Annual estimated screening compliance rates by jurisdiction

UNITED STATES	EUROPE	AUSTRALIA
63%	**38%**	**41%**
50-74 population 91,200,000	50-74 population 153,400,000	50-74 population 6,400,000
33,744,000 unscreened	95,108,000 unscreened	3,776,000 unscreened

Total 50-74 population, US/EU/AU **251M**
Total 50-74 unscreened population, US/EU/AU **132M**
NOT MEETING GLOBAL TARGET SCREENING RATES

Annual estimated screening market value* by jurisdiction

UNITED STATES	EUROPE	AUSTRALIA
$4.56BN	**$7.67BN**	**$320M**
91,200,000 potential tests	153,400,000 potential tests	6,400,000 potential tests

In America, Europe and Australia alone, the potential screening market aged 50-74 is worth **$12,550,000,000**
COLOSTAT® - NOT LIMITED TO SCREENING. MULTIPLE LIFE CYCLE OPPORTUNITIES.

Multiple avenues and market segments reduce risk and support a flexible and scalable business model

National Screening Program/ MBS Reimbursed

With its effectiveness and affordability, ColoSTAT® is well suited to mass market screening as a direct replacement for National Screening Programs led by Government, Health Insurers or GP's

Private Market

ColoSTAT® can be used by GP's or in Hospitals as a diagnostic

Led by Health Insurers, GP's, Hospitals

Secondary Triage

As a transition, ColoSTAT® can be used as a follow up secondary test for those that return a positive FIT test prior to undergoing an invasive Colonoscopy

Global Partnerships

Partnership, licencing, joint-venture options, market specific. Maximize IP.

Assumes a nominal test price point of AU$50

A MESSAGE FROM THE CHAIRMAN

SHANE TANNER

On behalf of the Rhythm Biosciences board, it gives me great pleasure to present our annual report for the 2019 Financial Year (FY19), a year in which we made strong progress in developing ColoSTAT®, our global, low cost, life saving blood test for the early detection of colorectal cancer.

Colorectal cancer remains the second biggest cause of cancer death in the world and continues to grow with over 1.8m new cases recorded each year. Rhythm's ColoSTAT® promises to be an important tool for early detection, and thus early treatment, of the disease.

Aimed at being low cost and effective, ColoSTAT® has the potential to reach the global mass market as a simple, patient friendly blood test for the early detection of colorectal cancer.

FY19 was an exciting year, culminating in the commencement of our technology entering a major clinical trial (Study 7).

Starting the clinical trial tops off a year in which Rhythm Biosciences advanced the reagent development program, which will enable the commercial testing kits to be finalised for the trial, which will play a pivotal role in bringing ColoSTAT® to market in our initial targeted jurisdictions of Australia, the United Kingdom and the broader European Union.

We also achieved the International Organization of Standardisation (ISO) EN 13485: 2016 standard for our Quality Management System, an essential certification for our future ability to manufacture our test kits, so as to control the supply and quality of our diagnostic technology ourselves.

The year also saw the ColoSTAT® trade mark registered to Rhythm's wholly owned subsidiary, Vision Tech Bio Pty Ltd in Australia, the United Kingdom, Europe and India; remaining pending only in the United States. With our IP secured – and our existing patent protection in Australia, China, Japan and the 13 key European countries we are targeting – we can confidently move to progressing our commercial plans for ColoSTAT® in these jurisdictions.

The year has positioned us to have our lead product, ColoSTAT®, submitted for registration and marketing approval in FY21, under both CE Mark in Europe and Therapeutic Goods Administration (TGA) in Australia.

In keeping with the progress in transition to commercialisation, we re-organised the company during the financial year, by appointing our chief operating officer, Glenn Gilbert, as chief executive officer, with the previous chief executive officer, Dr Trevor Lockett – a member of the CSIRO and clinical team that developed ColoSTAT® – taking the role of the company's technology director. We have enjoyed a seamless transition, which greatly strengthens our company's commercial and technology resolve.

Mr Gilbert will outline Rhythm's clinical and commercial progress in his report.

I also thank my fellow directors Trevor Lockett, Lou Panaccio and David White for their diligent efforts and counsel during the year.

Financially, we finished FY19 with a cash balance of $4.7 million, enough to fund our operations for the immediate future.

I also take the opportunity to thank all of our shareholders for their support.

There is still a way to go but the Board has every reason to feel very confident in the future of your company

CHIEF EXECUTIVE OFFICER'S REPORT

GLENN GILBERT

Over the 2019 Financial Year (FY19) Rhythm made solid progress in commercialising its global, low cost, life-saving test kit for the detection of colorectal cancer ColoSTAT®, highlighted by the commencement of the test's pivotal clinical trial, Study 7.

Study 7 is a major step in taking our life-saving technology from the research lab into the global market as an effective, low-cost blood test for the early detection of colorectal cancer. The trial will be a precursor for both CE Mark in Europe and Therapeutic Goods Administration (TGA) registration in Australia.

ColoSTAT®, which is based on 13 years of research and development by the CSIRO, is a potential alternative to the faecal immunochemical test (FIT). FIT is broadly used locally and internationally for the pre-assessment of colorectal cancer risk. However, it suffers limitations coupled with poor global participation rates.

The year began with the achievement of an important milestone, with Rhythm and its collaboration partner the CSIRO, completing a reagent development program, the isolation and characterisation of a set of antibodies central to the development of ColoSTAT®. ColoSTAT® uses antibodies to measure the levels of several proteins in the blood: the concentrations of these proteins in blood have been shown to vary with the presence or absence of colorectal cancer.

This work produced what was understood to be the preferred pair of antibodies identified for one of the lead biomarkers for the ColoSTAT® test. Intensive testing over the past several months indicated that the identified pairs were not performing as expected for this one biomarker. New antibodies have since been identified and appear to be suitable for use in ColoSTAT®. The other lead biomarker candidates were successfully established as part of the initial work and have now progressed into the current test development program.

The current test development program enables the development of the lead (and additional) biomarkers to be progressed, moving toward the development, optimisation and validation of the test. Once validated, these tests can move into a production transfer program to establish ongoing manufacture. The manufacture of these reagents (the target proteins and antibodies), is key in controlling the quality, cost and consistency of the test performance.

Work on the research, development and optimisation of the test continues. This work will be verified in a series of confirmatory analytical tests, making up Study 6. When the test development, optimisation and validation is completed, this will lay the foundation for the final kit.

The development of the final test kit remains Rhythm's key task. Additionally, Rhythm has identified preferred suppliers, consultants, manufacturers and has established a clear sequence of steps to de-risk the science and achieve successful registration.

The clinical trial, Study 7, is expected to recruit circa 1000-patients and will use blood samples from patients referred to a number of colonoscopy clinics in Melbourne and Adelaide. The clinical trial involves a prospective, cross-sectional, multi-centre study to evaluate the diagnostic performance of the ColoSTAT® in vitro diagnostic relative to colonoscopy (primary endpoint). Secondary endpoints of the study include assessing the ability of ColoSTAT® to detect advanced adenomas and a comparison of the performance of ColoSTAT® with the FIT; both relative to colonoscopy. We expect patient recruitment to be completed in FY20, with applications to the TGA and for CE mark to be then submitted in FY21.

In February we announced the first study site for the clinical trial, Adelaide's Lyell McEwin Hospital, with the hospital's Director of Gastroenterology, Professor Rajvinder Singh, engaged as principal investigator.

Further, Rhythm announced in June the addition of the second, third and fourth trial sites: Melbourne-based public health providers Monash Health, The Alfred Hospital and the Royal Melbourne Hospital, all leading Melbourne hospitals. At Monash Health the Head of Clinical Trials, Associate Professor Dr Stephen Pianko, a gastroenterologist, is the site's principal investigator, at The Alfred, Associate Professor Gregor Brown, the hospital's Head of Endoscopy is the site principal investigator, while at the Royal Melbourne Professor Finlay Macrae fills the role.

Rhythm also appointed clinical research organisation Plunkett Consulting Group to manage trial operations and provide rigour to the recruitment, monitoring and data collection, alongside Sonic Clinical Trials (SCT), which will facilitate the sample collection, processing, analytical testing, recording of results, transport and storage across the various participating clinical trial sites. Sonic Clinical Trials is a wholly owned subsidiary of Sonic Healthcare Limited (ASX: SHL), one of the world's largest medical diagnostics companies.

As we move through the development to manufacturing and completing the clinical trial, we are concurrently gearing up business development and commercialisation activity including:

- Engaging governments and identifying pathways for a screening mandate
- Developing partnerships with health insurance companies
- Developing partnerships with in vitro diagnostic device and pharmaceutical companies
- Developing partnerships and working with pathology laboratories

Further out, we expect to seek approval for ColoSTAT® in the United States. Preliminary assessment work is occurring, along with various go-to-market plans that may include FDA approval and/or early entry via a CLIA laboratory (lab developed test) pathway. Our primary addressable market is the 250 million people in the 50-74 year old population across the US, European Union and Australia. This population is recommended to participate in screening, irrespective of whether they have symptoms or not.

During the year the company consolidated its office and laboratory operations in one location at the Bio21 Institute in Parkville, Victoria. The Bio21 precinct is a hub of fast growing biotech and medical device enterprises.

I acknowledge the diligent efforts of our strong and dedicated team, our experienced board and the whole Rhythm family. All work with energy and purpose to deliver the goal of bringing to market a simple, low cost, patient friendly blood test for the detection of colorectal cancer, which can be easily used by millions to save lives worldwide.

Along with building shareholder value, we continue to be driven by this imperative.

Colorectal cancer is curable in 90% of cases if detected early, therefore patient participation in early screening is crucial.

We look forward to updating investors and the wider market on our progress in the coming months.

The Directors of Rhythm Biosciences Limited (Rhythm, the Group, or the Company) present their report for the financial year ended 30 June 2019.

Directors

The Directors at any time during the year, or since the end of the financial year, were as follows:

Mr Shane Tanner
Dr Trevor Lockett
Mr Louis (Lou) Panaccio
Mr David White

Principal Activities

Rhythm Biosciences Limited is developing and commercialising Australian medical diagnostics technology for sale in domestic and international markets. Its ColoSTAT® product in development aims to provide an accurate and early detection test for colorectal cancer

Corporate Information

Rhythm, a company limited by shares, is incorporated and domiciled in Australia. Rhythm has prepared a consolidated financial report incorporating the entity that it controlled during the financial year.

The registered office and principal place of business is located at Level 17, 500 Collins Street, Melbourne Victoria, Australia, 3000.

Review of Operations

The Group incurred a loss after income tax of $2,546,159 for the year ended 30 June 2019 (2018: $1,753,480).

The Chairman's Letter and Chief Executive Officer's Report contain a review of operations.

Significant Changes in the State of Affairs

There were no significant changes in the state of affairs of the consolidated entity during the financial year.

Future Developments

The Directors' do not foresee any unusual future event that may significantly negatively impact the Group's operations, results or state of affairs.

Rhythm's business model of developing diagnostic products for global markets will always bear some risk given the nature of technological development, competitors entering the market, changes in global healthcare, reliance on commercial partners and our ability to access capital to sustain operations. We cannot guarantee that Rhythm's technology will be widely adopted or sold by pathology laboratories. Moreover, the global Healthcare industry is an ever-evolving landscape where changes may impact our business opportunities.

Dividends

No dividends were paid or declared since the start of the financial year. No recommendation for payment has been made.

Directors and Company Secretaries

Names, qualifications and experience

Name	Shane Tanner
Title	Non-Executive Chairman
Experience and expertise	An experienced, accomplished and highly-respected professional in the Australian Healthcare sector, Shane has orchestrated and been responsible for numerous small and large scale acquisitions. He also has helped to establish and guide a number of significant businesses where he was deeply involved in growth and management upskilling.
Other current directorships	Paragon Care Limited Victory Offices Limited
Former directorships (last 3 years)	Funtastic Limited (resigned 31 July 2019) Zenitas Healthcare Limited (delisted 12 December 2018)
Interests in shares	1,600,000 fully paid ordinary shares
Interests in options	Nil

Name	Dr Trevor Lockett
Title	Technical Director
Experience and expertise	A molecular biologist by trade, Trevor Lockett received his PhD in biochemistry from the University of Adelaide and postdoctoral experience at the Rockefeller University in New York. With over 30 years of research experience, predominantly at the CSIRO, Trevor has led large, multidisciplinary research efforts in the areas of prostate cancer gene therapy, colorectal cancer prevention and the promotion of gastrointestinal health. In his role as Theme Leader, Colorectal Cancer and Gut Health, Trevor oversaw the research efforts leading to the technology that is to become ColoSTAT®.
Interests in shares	100,000 fully paid ordinary shares
Interests in options	2,000,000 options with an exercise price of 30 cents expiring on 7 December 2020

Name	David White
Title	Non-Executive Director
Experience and expertise	David is based in Chicago in the US and is currently the Vice President of Business Development for Bluechiip Limited. Bluechiip is an ASX listed company with unique technology that assists Biotech and Pharmaceutical companies to track biological samples in and out of cryogenic storage. Prior to Bluechiip, David spent 4 years with Planet Innovation in Project Management and Business Development roles, assisting PI in commercializing their IP in the Point of Care diagnostics space. David brings over 20 years' experience with diverse companies such as GenMark Diagnostics and Leica Biosystems in developing, marketing and selling IVD products in regulated markets. David's experience, networks and contacts within the US diagnostics market will accelerate the path to commercialization in this key geography.
Interests in shares	530,220 fully paid ordinary shares
Interests in options	Nil

Name	Lou Panaccio (appointed 1 August 2017)
Title	Non-Executive Director
Experience and expertise	A chartered accountant with extensive management experience in business and healthcare services. He is currently on the boards of ASX listed companies Sonic Healthcare Limited and Avita Medical Limited. Lou is also on the board of Unison Housing Limited. Lou has more than twenty years' experience as a board member of both public and private, for profit and not for profit companies. Previously, Lou was the CEO of Melbourne Pathology and Monash IVF, and also executive Chairman of Health Networks Australia.
Other current directorships	Sonic Healthcare Limited Avita Medical Limited
Former directorships (last 3 years)	Genera Biosystems Limited (resigned 28 June 2019)
Interests in shares	500,000 fully paid ordinary shares
Interests in options	Nil

'Other current directorships' quoted above are current directorships for listed entities only and excludes directorships of all other types of entities, unless otherwise stated.

'Former directorships (last 3 years)' quoted above are directorships held in the last 3 years for listed entities only and excludes directorships of all other types of entities, unless otherwise stated.

Company Secretaries

Adrien Wing is a certified practicing accountant. He previously practiced in the audit and corporate advisory divisions of a chartered accounting firm before working with a number of public companies listed on the ASX as a corporate and accounting consultant and company secretary.

Pauline Moffatt is a graduate of the Australian Institute of Company Directors (GAICD) and a fellow GIA ICSA of the Governance Institute of Australia. Ms Moffatt has a wealth of experience, providing specialised accounting and company secretary services to public companies for over 20 years.

Meetings of Directors

The following table sets out the number of Director meetings of the Company held during the financial year, and the number of meetings attended by each Director.

Director	Directors' Meetings	
	Held	Attended
Mr S Tanner	10	10
Dr T Lockett	10	10
Mr L Panaccio	10	9
Mr D White	10	9

Corporate Governance

Details on the Company's corporate governance procedures, policies and practices are at **www.rhythmbio.com**.

The Remuneration Report, which forms part of the Directors' report, sets out information about the remuneration of the Company's Directors and its Key Management Personnel for the financial year ended 30 June 2019.

Remuneration Report (Audited)

Names and positions held by Directors and Key Management Personnel at any time during the financial year were:

Name	Position	Date Appointed to Position
Mr Shane Tanner	Non-Executive Chairman	1 June 2017
Dr Trevor Lockett	Technical Director	27 November 2018 (previously Managing Director from 1 June 2017)
Mr Louis (Lou) Panaccio	Non-Executive Director	1 August 2017
Mr David White	Non-Executive Director	1 June 2017
Mr Glenn Gilbert	Chief Executive Officer	27 November 2018 (previously Chief Operating Officer from 21 May 2018)
Mr Adrien Wing	Company Secretary	1 June 2017

Directors' and Key Management Personnel Interests in Shares and Options

Directors' and Key Management Personnel's interests in the ordinary shares of Rhythm Biosciences Limited and options over ordinary shares as at the date of this report are detailed below:

Name	Position	Total Number of Ordinary Shares	Total Number of Options	Number of Performance Rights
Mr Shane Tanner	Non-Executive Chairman	1,600,000	-	-
Dr Trevor Lockett	Technical Director	100,000	2,000,000	-
Mr Louis (Lou) Panaccio	Non-Executive Director	500,000	-	-
Mr David White	Non-Executive Director	530,220	-	-
Mr Glenn Gilbert	Chief Executive Officer	-	1,000,000	504,200
Mr Adrien Wing	Company Secretary	11,100,000	-	-
		13,830,220	3,000,000	504,200

Remuneration Policy

The aim of the Company's remuneration policy is to align the interests of directors and employees with those of shareholders. To do this Rhythm sets remuneration levels that attract and retain highly skilled and experienced directors and employees; and motivates and rewards performance that advances the Company's strategic goals.

Remuneration Structure

The remuneration of Key Management Personnel and employees is structured in two parts:

- Fixed Remuneration, comprising: base salary, superannuation (payable under the Superannuation Guarantee Act) and other benefits in lieu of salary; and
- Variable Remuneration, which may comprise: a short-term incentive bonus (cash) and a long-term incentive in the form of options under the ESOP.

The Company aims to set the level of fixed remuneration at market levels for comparable jobs, in similarly structured and sized companies in the industry in which the Company operates. No advice from a remuneration consultant was sought during the financial year.

Short-Term Incentive Plan

The short-term incentive plan provides an incentive to employees to achieve an annual cash bonus on the achievement of corporate goals set at the beginning of each calendar year. These corporate goals are clearly defined, drive shareholder value and can be objectively measured. The percentage of an employee's base salary that can be earned through the Short-Term Incentive Plan (STIP) is set by the Board for Key Management Personnel and by Key Management Personnel for all other employees. At the end of the calendar year the Board assesses the level of achievement of these corporate goals. Payments made pursuant to the STIP are at the discretion of the Board.

Long-Term Incentive Plan

The purpose of the long-term incentive plan is to align the interests of directors, key management personnel and employees with those of the shareholders and provide reward for sustained achievement of the Group's strategic objectives. Rhythm's long-term incentive plan is implemented through the Employee Share Option Plan (ESOP).

During the 2018 year, 3,000,000 Options were issued to key management personnel. The fair value of employee share options was $194,100. This amount is expensed over the life of the relevant vesting periods. $85,922 was expensed in the current financial year (2018: $89,486).

The options were issued for nil consideration and granted in accordance with performance guidelines established by the Board.

The following Share Options arrangements existed at 30 June 2019:

Number of Options	Exercise Price ($)	Grant Date	Vesting Period	Vesting Date	Expiry Date	Holder	Fair Value per Option at Grant Date
2,000,000	$0.30	21.7.2017	1 year	21.7.2018	7.12.2020	Dr T Lockett	$0.045
1,000,000	$0.20	21.5.2018	Within 2 years	Various	21.5.2021	G Gilbert	$0.105
3,000,000	**Total ESOP Options**						

Vesting basis: to remain employed by Rhythm at vesting date (ranging from 12 to 24 months).

All options granted are in respect of ordinary shares in Rhythm Biosciences Limited and confer a right of one ordinary share for each option held.

Movement in the number of share options on issue

	2019 Number of Options	2019 Weighted Average Exercise Price (cents)	2018 Number of Options	2018 Weighted Average Exercise Price (cents)
Opening balance	3,000,000	26.67	-	-
Granted	-	-	3,000,000	26.67
Outstanding at year-end	**3,000,000**	**26.67**	**3,000,000**	**26.67**
Exercisable at year-end	2,500,000	28.00	-	-

During the 2019 financial year the Company granted 504,200 Performance Rights to Mr Glenn Gilbert as part of his remuneration. These Performance Rights lapse unless the market capitalisation of the Company at the end of the 12 month period (Relevant Period) after the issue is 20% more than the market capitalisation at the commencement of the Relevant Period. The fair value of employee Performance Rights was $45,277. This amount is expensed over the life of the relevant vesting periods. $8,831 was expensed in the current financial year (2018: $nil).

The Performance Rights were issued for nil consideration and granted in accordance with performance guidelines established by the Board.

Details are as follows:

Grant Date	Expiry Date	Vesting Periods	Granted	Converted	Lapsed/ Forfeited	Balance at End of the Year	Fair Value per Right at Grant Date
28.11.2018	27.11.2021	Various	504,200	-	-	504,200	$0.0897

Non-Executive Director Remuneration

The Board considers the level of remuneration necessary to attract and retain Directors with the skills and experience required by the Company at its stage of development. Non-executive Directors fees are paid within an aggregate limit which is approved by the shareholders from time to time. No retirement payments are made to Non-executive Directors.

For the 2019 financial year, the Australian based Non-executive Chairman's fees were $84,000 per annum while the Australian based Non-executive Directors' fees were $42,000 per annum. The United States based Non-executive Directors' fees were $36,000 per annum. No options were issued to Non-Executive Directors under the ESOP during the 2019 financial year.

Key Management Personnel Remuneration

Key Terms of the Technical Director's employment contract

The Company entered into an executive services agreement on 23 June 2017 for Dr Trevor Lockett to receive an annual salary of $200,000 (plus 15% superannuation). Trevor's engagement as Managing Director was for an initial term of one year, with an option for a further term of 12 months if agreed by both parties. The Company also issued Trevor 2,000,000 unlisted Options exercisable at 30 cents on or before 7 December 2020. Trevor may also receive short-term and/or long-term incentives. The payment of incentives is dependent upon Trevor's performance, as assessed by the Board, against key performance indicators relating to the Company's commercial, business and research and development goals. A bonus of $80,000 was paid during the 2019 financial year. Trevor transitioned to Technical Director effective 27 November 2018 following the appointment of Glenn Gilbert as CEO. The Company may terminate Trevor's employment upon 3 months' written notice.

Key Terms of the CEO's employment contract

The Company entered into an executive services agreement commencing on 21 May 2018 for Mr Glenn Gilbert as Chief Operating Officer to receive an annual salary of $190,000 (plus 9.5% superannuation). Glenn's employment is subject to an annual salary review to be conducted by the Company. Effective 27 November 2018, the Board appointed Glenn as Chief Executive Officer (CEO) and approved an increase to an annual salary of $260,000 (plus 9.5% superannuation). The Company has issued Glenn 1,000,000 unlisted Options which vest over a 2 year period, exercisable at 20 cents on or before 21 May 2021. Glenn may also receive short-term incentives dependent upon performance, as assessed against key performance indicators. A bonus of $23,750 was paid during the 2019 financial year. Performance Rights have been issued over 504,200 shares as detailed in Note 17 to the financial statements. The Company may terminate Glenn's employment upon 3 months' written notice.

Details of the remuneration of Directors and Key Management Personnel for the 2019 financial year are provided below:

	Short-term Benefits			Long-term benefits				
	Cash salary and fees ($)	Cash bonus ($)	Annual Leave Provision ($)	Long Service Leave Provision ($)	Post-employment Superannuation ($)	Equity-based compensation Options ($)	Total ($)	% of Total Performance Based
Non-Executive Directors								
S Tanner	84,000	-	-	-	-	-	84,000	-
D White	36,000	-	-	-	-	-	36,000	-
L Panaccio	42,000	-	-	-	-	-	42,000	-
Technical Director and CEO								
T Lockett	200,000	80,000	13,317	2,744	30,000	5,121	331,182	25.7
G Gilbert	231,910	23,750	23,605	1,001	22,031	89,632	391,929	28.9
Company Secretary								
A Wing	105,600	-	-	-	-	-	105,600	-
Total	**699,510**	**103,750**	**36,922**	**3,745**	**52,031**	**94,753**	**990,711**	

Details of the remuneration of Directors and Key Management Personnel for the 2018 financial year are provided below:

	Short-term Benefits			Long-term benefits				
	Cash salary and fees ($)	Cash bonus ($)	Annual Leave Provision ($)	Long Service Leave Provision ($)	Post-employment Superannuation ($)	Equity-based compensation Options ($)	Total ($)	% of Total Performance Based
Non-Executive Directors								
S Tanner	84,000	-	-	-	-	-	84,000	-
D White	36,000	-	-	-	-	-	36,000	-
L Panaccio	38,500	-	-	-	-	-	38,500	-
Managing Director and Executives								
T Lockett	192,064	-	-	-	28,810	83,879	304,753	27.5
G Gilbert	23,406	-	-	-	2,224	5,607	31,237	17.9
Company Secretary								
A Wing	114,400	-	-	-	-	-	114,400	-
Total	**488,370**	**-**	**-**	**-**	**31,034**	**89,486**	**608,890**	

Share-Based Payments

The Group operates an Employee Share Option Plan (ESOP). Each option provides the holder with the right to purchase an ordinary share in the parent entity at a pre-determined price. During the financial year ended 30 June 2019, nil (2018: 3,000,000) new options were issued pursuant to the Group's ESOP. Options offered to Rhythm Directors and staff are subject to a number of conditions which can restrict both vesting and the exercising of the options. At the date of the Directors Report a total of 3,000,000 options were on issue.

There were no ordinary shares issued during the financial year from the exercise of employee share options.

Option Holdings

The number of options over ordinary shares in the Company held during and at the end of the financial year by each Director and Key Management Personnel, including related parties, are set out below (refer also to Note 17 for further details):

	Balance at Beginning of Year	Granted During Year	Exercised During Year	Lapsed During Year	Balance at End of Year	Vested and Exercisable at End of Year	Unvested at End of Year
Non-Executive Directors							
S Tanner	-	-	-	-	-	-	-
D White	-	-	-	-	-	-	-
L Panaccio	-	-	-	-	-	-	-
Technical Director and CEO							
T Lockett	2,000,000	-	-	-	2,000,000	2,000,000	-
G Gilbert	1,000,000	-	-	-	1,000,000	500,000	500,000
Company Secretary							
A Wing	-	-	-	-	-	-	-
Total	**3,000,000**	**-**	**-**	**-**	**3,000,000**	**2,500,000**	**500,000**

Shareholdings

The number of ordinary shares in the Company held during and at the end of the 2019 financial year by each Director and Key Management Personnel of the Group, including related parties, are set out below.

	Balance at Beginning of Year	Share-based Compensation	Exercise of Options	Other Transactions with Company	On-market and Other Transactions	Balance at End of Year
Non-Executive Directors						
S Tanner	1,600,000	–	–	–	–	1,600,000
D White	500,000	–	–	–	30,220	530,220
L Panaccio	500,000	–	–	–	–	500,000
Technical Director and CEO						
T Lockett	100,000	–	–	–	–	100,000
G Gilbert	–	–	–	–	–	–
Company Secretary						
A Wing	11,100,000	–	–	–	–	11,100,000
TOTAL	**13,800,000**	**–**	**–**	**–**	**30,220**	**13,830,220**

The numbers of ordinary shares in the Company held during and at the end of the 2018 financial year by each Director and Key Management Personnel of the Group, including related parties, are set out below:

	Balance at Beginning of Year	Share-based compensation	Exercise of Options	Other Transactions with Company	On-market and Other Transactions	Balance at End of Year
Non-Executive Directors						
S Tanner	1,000,000	–	–	–	600,000	1,600,000
D White	500,000	–	–	–	–	500,000
L Panaccio	–	–	–	–	500,000	500,000
Managing Director and Executives						
T Lockett	–	–	–	–	100,000	100,000
G Gilbert	–	–	–	–	–	–
Company Secretary						
A Wing	11,000,000	–	–	–	100,000	11,100,000
Total	**12,500,000**	**–**	**–**	**–**	**1,300,000**	**13,800,000**

Additional Information

The earnings of the consolidated entity are summarised below:

Loss after income tax of $2,546,159 for the year ended 30 June 2019 (2018: $1,753,480).

The factors that are considered to affect total shareholders return ('TSR') are summarised below:

Share price at the end of the financial year was 18 cents (2018: 20.5 cents).

Basic Loss per share (cents per share) of 2.53 for the year ended 30 June 2019 (2018: 2.25).

This concludes the remuneration report, which has been audited.

Voting and comments made at the Company's 2018 Annual General Meeting

At the 2018 Annual General Meeting the 2018 Remuneration Report was voted upon by shareholders with no votes against the resolution.

Environmental Issues

Rhythm's operations are subject to certain environmental regulations under the laws of the Commonwealth and State. The Directors are not aware of any breaches during the period covered by this report.

Related Party Transactions

During the 2019 and 2018 financial years there were no transactions with related parties other than remuneration.

After Balance Date Events

There has been no matter or circumstance which has arisen since 30 June 2019 that has significantly affected or may significantly affect:

- The operations, in financial years subsequent to 30 June 2019, of the consolidated entity, or
- The results of those operations, or
- The state of affairs, in financial years subsequent to 30 June 2019, of the consolidated entity.

Proceedings on Behalf of the Company

No person has applied for leave of court to bring proceedings on behalf of the Company to intervene in any proceedings to which the Company is a party for the purpose of taking responsibility on behalf of the Company for all or any part of these proceedings.

Indemnity and Insurance of Officers

The Company has paid a premium for Directors' and Officers' Liability (Management Liability) Insurance.

Under the Company's constitution:

i. To the extent permitted by law and subject to the restrictions in sections 199A and 199B of the Corporations Act 2001, the Company indemnifies every person who is or has been an officer of the Company against any liability (other than for legal costs) incurred by that person as an officer of the Company.

ii. To the extent permitted by law and subject to the restrictions in sections 199A and 199B of the Corporations Act 2001, the Company indemnifies every person who is or has been an officer of the Company against reasonable legal costs incurred in defending an action for a liability incurred by that person as an officer of the Company.

The Company insures its Directors, Company Secretary and executive officers under a Management Liability Insurance policy. Under the Company's Management Liability Insurance Policy, the Company cannot release to any third party or otherwise publish details of the nature of the liabilities insured by the policy or the amount of the premium. Accordingly, the Company relies on section 300(9) of the Corporations Act 2001 to exempt it from the requirement to disclose the nature of the liability insured against and the premium amount of the relevant policy

Indemnity and Insurance of Auditor

The company has not, during or since the end of the financial year, indemnified or agreed to indemnify the auditor of the company or any related entity against a liability incurred by the auditor. During the financial year, the company has not paid a premium in respect of a contract to insure the auditor of the company or any related entity.

Auditors' Independence Declaration

A copy of the auditors' independence declaration as required under s307C of the Corporations Act 2001 is set out on page 24.

Non-Audit Services

BDO East Coast Partnership were paid $20,520 (2018: $45,800) for non-audit services during the 2019 financial year.

The directors are satisfied that the provision of non-audit services during the financial year, by the auditor, is compatible with the general standard of independence for auditors imposed by the Corporations Act 2001 for the following reasons:

- all non-audit services have been reviewed and approved to ensure that they do not impact the integrity and objectivity of the auditor; and
- none of the services undermine the general principles relating to auditor independence as set out in APES 110 Code of Ethics for Professional Accountants issued by the Accounting Professional and Ethical Standards Board, including reviewing or auditing the auditor's own work, acting in a management or decision-making capacity for the company, acting as advocate for the company or jointly sharing economic risks and rewards.

Officers of the Company who are Former Partners of BDO East Coast Partnership

There are no officers of the company who are former partners of BDO East Coast Partnership.

This report is made in accordance with a resolution of the Directors

Shane Tanner
Chairman

Melbourne, Australia
Dated this 29th day of August 2019

Tel: +61 3 9603 1700
Fax: +61 3 9602 3870
www.bdo.com.au

Collins Square, Tower Four
Level 18, 727 Collins Street
Melbourne VIC 3008
GPO Box 5099 Melbourne VIC 3001
Australia

DECLARATION OF INDEPENDENCE BY JAMES MOONEY TO THE DIRECTORS OF RHYTHM BIOSCIENCES LIMITED

As lead auditor of Rhythm Biosciences Limited for the year ended 30 June 2019, I declare that, to the best of my knowledge and belief, there have been:

1. No contraventions of the auditor independence requirements of the *Corporations Act 2001* in relation to the audit; and
2. No contraventions of any applicable code of professional conduct in relation to the audit.

This declaration is in respect of Rhythm Biosciences Limited and the entities it controlled during the period.

James Mooney
Partner

BDO East Coast Partnership

Melbourne, 29 August 2019

Consolidated Statement of Profit or Loss and Other Comprehensive Income

	Notes	2019 ($)	2018 ($)
Other Income			
Interest Income		141,066	64,476
Research and Development Tax Refund		1,027,618	-
Expenses			
Employment related costs	4	(1,617,926)	(782,948)
Office and compliance costs		(536,915)	(321,948)
Research and development costs		(980,283)	(359,111)
Marketing and investor relations		(302,934)	(93,477)
Occupancy costs		(122,455)	(20,778)
Travel and meetings		(88,964)	(18,837)
Depreciation	10	(29,395)	(1,463)
IPO listing costs		-	(189,322)
Amortisation of intangibles	9	(35,971)	(30,072)
Total Expenses		**(3,714,843)**	**(1,817,956)**
Loss Before Income Tax		**(2,546,159)**	**(1,753,480)**
Income tax expense	5	-	-
Loss After Tax		**(2,546,159)**	**(1,753,480)**
Other comprehensive income		-	-
Total Comprehensive Loss for the Year		**(2,546,159)**	**(1,753,480)**
Loss Per Share			
Basic loss per share (cents per share)	6	(2.53)	(2.25)
Diluted loss per share (cents per share)	6	(2.53)	(2.25)

The financial statements should be read in conjunction with the accompanying notes.

Consolidated Statement of Financial Position

	Notes	30 June 2019 ($)	30 June 2018 ($)
Current Assets			
Cash and cash equivalents	7	4,728,315	7,780,173
Trade and other receivables	8	797,697	35,232
Other financial assets – term deposit		45,000	45,000
Prepayments		34,298	8,872
Total Current Assets		5,605,310	7,869,277
Non-Current Assets			
Intangible assets	9	533,957	569,928
Property, plant and equipment	10	90,165	9,298
Total Non-Current Assets		624,122	579,226
Total Assets		6,229,432	8,448,503
Current Liabilities			
Trade and other payables	11	302,133	138,009
Provisions	12	70,862	9,370
Total Current Liabilities		372,995	147,379
Non Current Liabilities			
Provisions	12	6,719	-
Total Non-Current Liabilities		6,719	-
Total Liabilities		379,714	147,379
Net Assets		5,849,718	8,301,124
Equity			
Issued capital	13	10,037,245	10,037,245
Reserves	14	184,239	89,486
Accumulated losses		(4,371,766)	(1,825,607)
Total Equity		5,849,718	8,301,124

The financial statements should be read in conjunction with the accompanying notes.

Consolidated Statement of Changes in Equity

	Issued Capital ($)	Reserves ($)	Accumulated Losses ($)	Total ($)
Balance at 1 July 2018	10,037,245	89,486	(1,825,607)	8,301,124
Loss attributable to members	-	-	(2,546,159)	(2,546,159)
Share-based payments expense (Note 17)	-	94,753	-	94,753
Balance at 30 June 2019	10,037,245	184,239	(4,371,766)	5,849,718
Balance at 1 July 2017	1,495,000	-	(72,127)	1,422,873
Loss attributable to members	-	-	(1,753,480)	(1,753,480)
Share-based payments expense (Note 17)	-	89,486	-	89,486
Shares issued (net of issue costs) (Note 13)	8,542,245	-	-	8,542,245
Balance at 30 June 2018	10,037,245	89,486	(1,825,607)	8,301,124

Consolidated Statement of Cash Flows

	Notes	2019 ($)	2018 ($)
Cash Flow from Operating Activities			
Interest received		145,753	52,427
Payments to suppliers and employees		(3,371,145)	(1,703,726)
Research and development tax refund		283,796	-
Net Cash Used In Operating Activities	15	(2,941,596)	(1,651,299)
Cash Flow from Investing Activities			
Payments for term deposits		-	(45,000)
Payments for intangibles		-	(300,000)
Purchase of property, plant and equipment		(110,262)	(10,761)
Net Cash Used In Investing Activities		(110,262)	(355,761)
Cash Flow from Financing Activities			
Proceeds from issue of ordinary shares		-	9,042,500
Payment of share issue costs		-	(750,254)
Net Cash Provided By Financing Activities		-	8,292,246
Net (Decrease)/Increase In Cash Held		(3,051,858)	6,285,186
Cash and cash equivalents at beginning of financial year		7,780,173	1,494,987
Cash And Cash Equivalents at End of Financial Year	7	4,728,315	7,780,173

The financial statements should be read in conjunction with the accompanying notes.

Note 1: Statement of Significant Accounting Policies

The consolidated financial statements and notes represent those of Rhythm Biosciences Limited and Controlled Entities (the 'Consolidated Group' or 'Group'). The separate financial statements of the parent entity, Rhythm Biosciences Limited, have not been presented within this financial report as permitted by amendments made to the Corporations Act 2001. The financial report covers the economic entities of Rhythm Biosciences Limited and its controlled entities as an economic entity for the year ended 30 June 2019. Comparatives are disclosed for the year ended 30 June 2018.

The financial statements are presented in Australian dollars, which is the Group's functional and presentation currency. The financial statements were authorised for issue on 29 August 2019 by the Directors of the Company.

Statement of Compliance

These financial statements are general purpose financial statements which have been prepared in accordance with the Corporations Act 2001, Australian Accounting Standards and Interpretations, and comply with other requirements of the law. The financial statements comprise the consolidated financial statements of the Group. For the purposes of preparing the consolidated financial statements, the Company is a for-profit entity. Compliance with Australian Accounting Standards ensures that the financial statements and notes of the company and the Group comply with International Financial Reporting Standards ('IFRS').

Basis of Preparation

Australian Accounting Standards set out accounting policies that the AASB has concluded would result in a financial report containing relevant and reliable information about transactions, events and conditions to which they apply. Material accounting policies adopted in the preparation of this financial report are presented below. They have been consistently applied unless otherwise stated.

The financial report has been prepared on an accruals basis and is based on historical costs, modified, where applicable, by the measurement at fair value of selected non-current assets, financial assets, and financial liabilities.

Accounting Policies

Principles of Consolidation

The consolidated financial statements incorporate the assets and liabilities of all subsidiaries of Rhythm Biosciences Limited ('company' or 'parent entity') as at 30 June 2019 and the results of all subsidiaries for the year then ended.

Subsidiaries are all those entities over which the consolidated entity has control. The consolidated entity controls an entity when the consolidated entity is exposed to, or has rights to, variable returns from its involvement with the entity and has the ability to affect those returns through its power to direct the activities of the entity. Subsidiaries are fully consolidated from the date on which control is transferred to the consolidated entity. They are de-consolidated from the date that control ceases.

Intercompany transactions, balances and unrealised gains on transactions between entities in the consolidated entity are eliminated. Unrealised losses are also eliminated unless the transaction provides evidence of the impairment of the asset transferred. Accounting policies of subsidiaries have been changed where necessary to ensure consistency with the policies adopted by the consolidated entity.

The acquisition of subsidiaries is accounted for using the acquisition method of accounting. A change in ownership interest, without the loss of control, is accounted for as an equity transaction, where the difference between the consideration transferred and the book value of the share of the non-controlling interest acquired is recognised directly in equity attributable to the parent.

Operating Segments

Operating segments are presented using the 'management approach', where the information presented is on the same basis as the internal reports provided to the Chief Operating Decision Makers ('CODM'). The CODM is responsible for the allocation of resources to operating segments and assessing their performance.

Revenue Recognition

Revenue is recognised at the fair value of the consideration received net of the amount of goods and services tax (GST) payable to the taxation authority. For each contract with a customer, the consolidated entity: identifies the contract with a customer; identifies the performance obligations in the contract; determines the transaction price which takes into account estimates of variable consideration and the time value of money; allocates the transaction price to the separate performance obligations on the basis of the relative stand-alone selling price of each distinct good or service to be delivered; and recognises revenue when or as each performance obligation is satisfied in a manner that depicts the transfer to the customer of the goods or services promised.

Interest income is recognised as it accrues, taking into account the effective yield on the financial asset.

Goods and Services Tax

Revenue, expenses and assets are recognised net of the amount of goods and services tax (GST), except where the amount of GST incurred is not recoverable from the taxation authority. In these circumstances the GST is recognised as part of the cost of acquiring the asset or as part of an item of expense.

Receivables and payables are stated with the amount of GST included.

The net amount of GST recoverable from, or payable to, the taxation authority is included as a current asset or liability in the statement of financial position.

Cash flow is included in the statement of cash flow on a gross basis. The GST components of cash flow arising from investing and financing activities, which are recoverable from, or payable to, the taxation authority, are classified as operating cash flow.

Income Tax

Income tax expense represents the sum of the tax currently payable and deferred tax.

Deferred tax is accounted for using the balance sheet liability method in respect of temporary differences arising between the tax bases of assets and liabilities and their carrying amounts in the financial statements. No deferred income tax will be recognised from the initial recognition of an asset or liability, excluding a business combination, where there is no effect on accounting or taxable profit or loss.

Deferred tax is calculated at the tax rates that are expected to apply in the period when the asset is realised or liability is settled. Deferred tax is credited in the income statement except where it relates to items that may be credited directly to equity, in which case the deferred tax is adjusted directly against equity.

Deferred income tax assets are recognised to the extent that it is probable that future tax profits will be available, against which deductible temporary differences can be utilised. No deferred tax assets have been recognised on the balance sheet as at 30 June 2019, as the probability of deriving a benefit is uncertain.

The amount of benefits brought to account or which may be realised in the future is based on the assumption that no adverse change will occur in income taxation legislation and the expectation that the Group will derive sufficient future assessable income to enable the benefit to be realised and comply with the conditions of deductibility imposed by the law.

Current and Non-current Classification

Assets and liabilities are presented in the statement of financial position based on current and non-current classification.

An asset is classified as current when: it is either expected to be realised or intended to be sold or consumed in the consolidated entity's normal operating cycle; it is held primarily for the purpose of trading; it is expected to be realised within 12 months after the reporting period; or the asset is cash or cash equivalent unless restricted from being exchanged or used to settle a liability for at least 12 months after the reporting period. All other assets are classified as non-current.

A liability is classified as current when: it is either expected to be settled in the consolidated entity's normal operating cycle; it is held primarily for the purpose of trading; it is due to be settled within 12 months after the reporting period; or there is no unconditional right to defer the settlement of the liability for at least 12 months after the reporting period. All other liabilities are classified as non-current.

Deferred tax assets and liabilities are always classified as non-current.

Cash and Cash Equivalents

Cash and cash equivalents includes cash on hand, deposits held at call with financial institutions, other short-term, highly liquid investments with original maturities of three months or less that are readily convertible to known amounts of cash and which are subject to an insignificant risk of changes in value. For the statement of cash flows presentation purposes, cash and cash equivalents also includes bank overdrafts, which are shown within borrowings in current liabilities on the statement of financial position.

Trade and Other Receivables

Trade receivables are initially recognised at fair value and subsequently measured at amortised cost using the effective interest method, less any allowance for expected credit losses. Trade receivables are generally due for settlement within 30 days.

The consolidated entity has applied the simplified approach to measuring expected credit losses, which uses a lifetime expected loss allowance. To measure the expected credit losses, trade receivables have been grouped based on days overdue.

Other receivables are recognised at amortised cost, less any allowance for expected credit losses.

Intangibles

Research and Development

Expenditure during the research phase of a project is recognised as an expense when incurred. Product development costs are capitalised only when each of the following specific criteria has been satisfied:

i. Technical feasibility of completing development of the product and obtaining approval by regulatory authorities.

ii. Ability to secure a commercial partner for the product.

iii. Availability of adequate technical, financial and other resources to complete development of the product, obtain regulatory approval and secure a commercial partner.

iv. Reliable measurement of expenditure attributable to the product during its development.

v. High probability of the product entering a major diagnostic market.

Capitalised development costs have a finite life and are amortised on a systematic basis over the period from when the product becomes available for use and ceases at the earlier of the date the asset is expected to exit the market or that the asset is classified as held for sale (or included in a disposal group that is classified as held for sale) in accordance with AASB 5.

Other Intangible Assets

Other intangible assets comprise licences and are stated at cost less accumulated amortisation and impairment losses.

Property, Plant and Equipment

Each class of property, plant and equipment is carried at cost or fair value less, where applicable, any accumulated depreciation and impairment.

Plant and Equipment

The carrying amount of plant and equipment is reviewed annually by the Directors to ensure it is not in excess of the recoverable amount from these assets. The recoverable amount is assessed on the basis of the expected net cash flows that will be received from the assets' employment and subsequent disposal. The expected net cash flows have been discounted to their present values in determining recoverable amounts.

Subsequent costs are included in the asset's carrying amount or recognised as a separate asset, as appropriate, only when it is probable that future economic benefits associated with the item will flow to the Group and the cost of the item can be measured reliably. All other repairs and maintenance are charged to the income statement during the financial period in which they are incurred.

Depreciation

The depreciable amount of all fixed assets, including building and capitalised lease assets but excluding freehold land, is depreciated on a straight line basis over their useful lives to the Group commencing from the time the asset is held ready for use. Items of property, plant and equipment, are depreciated over their estimated useful lives.

The depreciation rates for each class of asset are:

Class of Non-Current Asset	Depreciation Rate	Estimated Useful Lives
Office Equipment	10%	10 years
Computer Equipment	33.3%	3 years
Laboratory Equipment	33.3%	3 years

The assets' residual values and useful lives are reviewed, and adjusted if appropriate, at each end of reporting period.

An asset's carrying amount is written down immediately to its recoverable amount if the asset's carrying amount is greater than its estimated recoverable amount.

Impairment of Non-financial Assets

At each reporting date the Group reviews the carrying values of its tangible and intangible assets to determine whether there is any indication that those assets have been impaired. If such an indication exists, the recoverable amount of the asset, being the higher of the asset's fair value less costs to sell and value in use, is compared to the asset's carrying value. Any excess of the asset's carrying value over its recoverable amount is expensed to the statement of comprehensive income.

Impairment testing is performed annually for intangible assets with indefinite lives and capitalised development costs not yet ready for use.

Where it is not possible to estimate the recoverable amount of an individual asset, the Group estimates the recoverable amount of the cash-generating unit to which the asset belongs.

Payables

Liabilities are recognised for amounts to be paid in the future for goods or services received. Due to their short-term nature they are measured at amortised cost and are not discounted. Trade accounts payable and other creditors are normally settled within 60 days.

Employee Entitlements

Short-term and long-term employee benefits

A liability is recognised for benefits accruing to employees for wages and salaries and annual leave in the year the related service is rendered.

Liabilities recognised in respect of short-term employee benefits are measured at their nominal values using the remuneration rate expected to apply at the time of settlement. Liabilities recognised in respect of long term employee benefits are measured as the present value of the estimated future cash outflows to be made by the Group in respect of services provided by employees up to reporting date.

Contributions are made by the Group to employee superannuation funds and are charged as expenses when incurred

Share-based compensation

Equity-settled and cash-settled share-based compensation benefits are provided to employees.

Equity-settled transactions are awards of shares, or options over shares, that are provided to employees in exchange for the rendering of services. Cash-settled transactions are awards of cash for the exchange of services, where the amount of cash is determined by reference to the share price.

The cost of equity-settled transactions are measured at fair value on grant date. Fair value is independently determined using either the Binomial or Black-Scholes option pricing or models that takes into account the exercise price, the term of the option, the impact of dilution, the share price at grant date and expected price volatility of the underlying share, the expected dividend yield and the risk free interest rate for the term of the option, together with non-vesting conditions that do not determine whether the consolidated entity receives the services that entitle the employees to receive payment. No account is taken of any other vesting conditions.

The cost of equity-settled transactions are recognised as an expense with a corresponding increase in equity over the vesting period. The cumulative charge to profit or loss is calculated based on the grant date fair value of the award, the best estimate of the number of awards that are likely to vest and the expired portion of the vesting period. The amount recognised in profit or loss for the period is the cumulative amount calculated at each reporting date less amounts already recognised in previous periods.

The cost of cash-settled transactions is initially, and at each reporting date until vested, determined by applying either the Binomial or Black-Scholes option pricing model, taking into consideration the terms and conditions on which the award was granted. The cumulative charge to profit or loss until settlement of the liability is calculated as follows:

- during the vesting period, the liability at each reporting date is the fair value of the award at that date multiplied by the expired portion of the vesting period.
- from the end of the vesting period until settlement of the award, the liability is the full fair value of the liability at the reporting date.

All changes in the liability are recognised in profit or loss. The ultimate cost of cash-settled transactions is the cash paid to settle the liability.

Market conditions are taken into consideration in determining fair value. Therefore any awards subject to market conditions are considered to vest irrespective of whether or not that market condition has been met, provided all other conditions are satisfied.

If equity-settled awards are modified, as a minimum an expense is recognised as if the modification has not been made. An additional expense is recognised, over the remaining vesting period, for any modification that increases the total fair value of the share-based compensation benefit as at the date of modification.

If the non-vesting condition is within the control of the consolidated entity or employee, the failure to satisfy the condition is treated as a cancellation. If the condition is not within the control of the consolidated entity or employee and is not satisfied during the vesting period, any remaining expense for the award is recognised over the remaining vesting period, unless the award is forfeited.

Issued Capital

Ordinary shares are classified as equity.

Incremental costs directly attributable to the issue of new shares or options are shown in equity as a deduction, net of tax, from the proceeds.

Financial Instruments

Recognition

Financial instruments are initially measured at cost on transaction date, which includes transaction costs, when the related contractual rights or obligations exist. Subsequent to initial recognition these instruments are measured as set out below.

Receivables

Receivables are non-derivative financial assets with fixed or determinable payments that are not quoted in an active market and are stated at amortised cost using the effective interest rate method.

Financial liabilities

Non-derivative financial liabilities are recognised at amortised cost, comprising original debt less principal payments and amortisation.

Impairment

An 'expected credit loss' ('ECL') model is used to recognise an allowance. Impairment is measured using a 12-month ECL method unless the credit risk on a financial instrument has increased significantly since initial recognition in which case the lifetime ECL method is adopted.

Earnings per share

Basic earnings per share is calculated by dividing the profit attributable to the owners of Rhythm Biosciences Limited, excluding any costs of servicing equity other than ordinary shares, by the weighted average number of ordinary shares outstanding during the financial year, adjusted for bonus elements in ordinary shares issued during the financial year.

Diluted earnings per share adjusts the figures used in the determination of basic earnings per share to take into account the after income tax effect of interest and other financing costs associated with dilutive potential ordinary shares and the weighted average number of shares assumed to have been issued for no consideration in relation to dilutive potential ordinary shares.

Goods and Services Tax ('GST') and Other Similar Taxes

Revenues, expenses and assets are recognised net of the amount of associated GST, unless the GST incurred is not recoverable from the tax authority. In this case it is recognised as part of the cost of the acquisition of the asset or as part of the expense.

Receivables and payables are stated inclusive of the amount of GST receivable or payable. The net amount of GST recoverable from, or payable to, the tax authority is included in other receivables or other payables in the statement of financial position.

Cash flows are presented on a gross basis. The GST components of cash flows arising from investing or financing activities which are recoverable from, or payable to the tax authority, are presented as operating cash flows.

Commitments and contingencies are disclosed net of the amount of GST recoverable from, or payable to, the tax authority.

Comparative Figures

When required by Accounting Standards, comparative figures have been adjusted to conform to changes in presentation for the current financial year.

Critical Accounting Estimates and Judgments

The Directors evaluate estimates and judgments incorporated into the financial report based on historical knowledge and best available current information. Estimates assume a reasonable expectation of future events and are based on current trends and economic data, obtained both externally and within the Group.

Key Estimates

Share-based payments

Rhythm operates an Employee Share Option Plan (ESOP). The non-cash expense of issuing Performance Rights and Options is calculated using a binomial valuation model or Black-scholes option pricing model. These models require the input of a number of variables including an estimate of future volatility and a risk-free interest rate. Refer to Note 17 to the financial statements.

Intangible assets

The consolidated entity assesses impairment of non-financial indefinite life intangible assets and intangible assets not yet ready for use at each reporting date by evaluating conditions specific to the consolidated entity and to the particular asset that may lead to impairment. If an impairment trigger exists, the recoverable amount of the asset is determined. This involves fair value less costs of disposal or value-in-use calculations, which incorporate a number of key estimates and assumptions. Refer to Note 9 to the financial statements.

Adoption of New and Revised Accounting Standards

During the current year, the Group has adopted all of the new and revised Australian Accounting Standards and Interpretations applicable to its operations which became mandatory.

The adoption of these Standards has not impacted the financial statements.

New Accounting Standards for Application in Future Periods

The Board has assessed the impact of the new, but not yet mandatory, accounting standards issued by Australian Accounting Standards Board (AASB).

AASB 16 Leases

This standard is applicable to annual reporting periods beginning on or after 1 January 2019. The standard replaces AASB 117 'Leases' and for lessees will eliminate the classifications of operating leases and finance leases. Subject to exceptions, a 'right-of-use' asset will be capitalised in the statement of financial position, measured at the present value of the unavoidable future lease payments to be made over the lease term. The exceptions relate to short-term leases of 12 months or less and leases of low-value assets (such as personal computers and small office furniture) where an accounting policy choice exists whereby either a 'right-of-use' asset is recognised or lease payments are expensed to profit or loss as incurred. A liability corresponding to the capitalised lease will also be recognised, adjusted for lease prepayments, lease incentives received, initial direct costs incurred and an estimate of any future restoration, removal or dismantling costs. Straight-line operating lease expense recognition will be replaced with a depreciation charge for the leased asset (included in operating costs) and an interest expense on the recognised lease liability (included in finance costs). In the earlier periods of the lease, the expenses associated with the lease under AASB 16 will be higher when compared to lease expenses under AASB 117. However EBITDA (Earnings Before Interest, Tax, Depreciation and Amortisation) results will be improved as the operating expense is replaced by interest expense and depreciation in profit or loss under AASB 16. For classification within the statement of cash flows, the lease payments will be separated into both a principal (financing activities) and interest (either operating or financing activities) component. For lessor accounting, the standard does not substantially change how a lessor accounts for leases.

The consolidated entity has adopted this standard from 1 July 2019 and minimal impact of its adoption is expected as there are currently no significant lease agreements in place.

Note 2: Parent Information

	2019 ($)	2018 ($)
Statement of Financial Position		
Current assets	5,554,851	7,846,095
Non-current assets	517,773	579,226
Total Assets	**6,072,624**	**8,425,321**
Current liabilities	216,187	144,868
Non-Current Liabilities	6,719	-
Total Liabilities	**222,906**	**144,868**
Issued Capital	10,037,245	10,037,245
Reserves	184,239	89,486
Accumulated losses	(4,371,766)	(1,823,919)
Total Equity	**5,849,718**	**8,302,812**
Statement of Comprehensive Income	**2019 ($)**	**2018 ($)**
Total loss	(2,547,847)	(1,751,792)
Total Comprehensive Income	**(2,547,847)**	**(1,751,792)**

Guarantees

The Parent Company has not entered into any guarantees in relation to its subsidiary.

Commitments and Contingent Liabilities

At 30 June 2019, the Parent Company had commitments as disclosed in Note 23 and no contingent liabilities (2018: Nil).

Significant Accounting Policies

The accounting policies of the parent entity are consistent with those of the consolidated entity, as disclosed in Note 1, except for investments in subsidiaries which are accounted for at cost, less any impairment, in the parent entity.

Note 3: Controlled Entities

Controlled Entities Consolidated	Country of Incorporation	Percentage Owned (%) 2019	Percentage Owned (%) 2018
Vision Tech Bio Pty Ltd	Australia	100%	100%

** Percentage of voting power in proportion to ownership*

Note 4: Employment Related Costs

	2019 ($)	2018 ($)
Loss from continuing activities before income tax after charging the following items:		
Employment Related Costs		
Staff salaries and wages	1,108,221	392,391
Non-Executive Directors' fees	162,000	158,500
Superannuation	109,636	63,690
Share-based payments expense (Note 17)	94,753	89,486
Other employment related expenses	143,316	78,881
Total	**1,617,926**	**782,948**

Note 5: Income Tax Relating to Continuing Activities

	2019 ($)	2018 ($)
Prima facie income tax benefit from continuing activities before income tax at 27.5% (2018: 27.5%)	700,194	482,207
Add/(subtract) Tax Effect:		
- Research and development claim	282,595	-
- Share based payments expense	(26,057)	(24,609)
- Other non-deductible expenditure	(2,885)	(1,338)
- Tax losses and temporary differences not brought to account	(953,847)	(456,260)
Income Tax Expense	-	-

Total tax losses and temporary differences not brought to account $1,494,231 (2018: $723,666).

Note 6: Loss Per Share

	2019 ($)	2018 ($)
The following reflects the income and share data used in the calculations of basic and diluted loss per share:		
Loss used in calculating basic and diluted earnings per share	(2,546,159)	(1,753,480)
	2019 No. of Shares	**2018 No. of Shares**
Weighted average number of ordinary shares used in calculating basic loss per share	100,750,000	77,923,288
Basic and Diluted Loss Per Share (cents)	(2.53)	(2.25)

Calculation of diluted loss per share

Potential ordinary shares are considered to be antidilutive, therefore diluted loss per share is equivalent to the basic loss per share.

Note 7: Cash and Cash Equivalents

	2019 ($)	2018 ($)
Cash at bank	728,315	780,173
Short term deposits	4,000,000	7,000,000
	4,728,315	7,780,173

Note 8: Trade and Other Receivables

	2019 ($)	2018 ($)
GST receivable	46,513	23,183
Interest receivable	7,362	12,049
Research and Development Tax Refund(i)	743,822	-
	797,697	35,232

(i) This tax refund was received from the ATO on 21 August 2019 and relates to the 2019 financial year.

Note 9: Intangible Assets

	2019 ($)	2018 ($)
Intellectual Property		
Licences (i)	533,957	569,928
	533,957	569,928

	1 July 2018 – 30 June 2019 ($)	1 July 2017 – 30 June 2018 ($)
Movement in Carrying Amounts		
Balance at the beginning of the year	569,928	50,000
Additions	-	550,000
Amortisation (i)	(35,971)	(30,072)
Balance at the End of the Year	533,957	569,928

(i) A licence has been granted by the Commonwealth Scientific and Industrial Research Organisation ("CSIRO") on 23 August 2017 and is being amortised on a straight line basis over a period of 17 years based on contract terms.

Note 10: Property, Plant and Equipment

	2019 ($)	2018 ($)
Computers – at cost	30,983	10,055
Accumulated depreciation	(9,451)	(1,453)
	21,532	8,602
Office equipment – at cost	1,986	706
Accumulated depreciation	(396)	(10)
	1,590	696
Laboratory equipment - at cost	88,054	-
Accumulated depreciation	(21,011)	-
	67,043	-
Total	90,165	9,298

	Computer Equipment ($)	Office Equipment ($)	Laboratory Equipment ($)	Total ($)
Movement in Carrying Amounts				
Balance at the beginning of the year	8,602	696	-	9,298
Additions	20,928	1,280	88,054	110,262
Depreciation	(7,998)	(386)	(21,011)	(29,395)
Balance at the End of the Year	21,532	1,590	67,043	90,165

Note 11: Trade and Other Payables

	2019 ($)	2018 ($)
Trade creditors	207,156	79,287
Accruals	94,977	58,722
	302,133	138,009

Note 12: Provisions

	2019 ($)	2018 ($)
Current		
Provision for Annual Leave	70,862	9,370
Non-Current		
Provision for Long Service Leave	6,719	-
	77,581	9,370

Note 13: Issued Capital

	2019 (No.)	2018 (No.)	2019 ($)	2018 ($)
Ordinary Shares Fully Paid				
Balance at the beginning of the year	100,750,000	52,075,000	10,037,245	1,495,000
Issued during the year	-	48,675,000	-	9,442,500
Equity raising expenses	-	-	-	(900,255)
Balance at the End of the Year	100,750,000	100,750,000	10,037,245	10,037,245

Ordinary Shares

Ordinary shares entitle the holder to participate in dividends and the proceeds on the winding up of the company in proportion to the number of and amounts paid on the shares held. The fully paid ordinary shares have no par value and the company does not have a limited amount of authorised capital.

On a show of hands every member present at a meeting in person or by proxy shall have one vote and upon a poll each share shall have one vote.

Capital Risk Management

The consolidated entity's objectives when managing capital is to safeguard its ability to continue as a going concern, so that it can provide returns for shareholders and benefits for other stakeholders and to maintain an optimum capital structure to reduce the cost of capital.

Capital is regarded as total equity, as recognised in the statement of financial position, plus net debt. Net debt is calculated as total borrowings less cash and cash equivalents. In order to maintain or adjust the capital structure, the consolidated entity may adjust the amount of dividends paid to shareholders, return capital to shareholders, issue new shares or sell assets to reduce debt.

The consolidated entity would look to raise capital when an opportunity to invest further into development and commercialisation or in a business or company was seen as value adding relative to the current company's share price at the time of the investment. The consolidated entity is not actively pursuing additional investments in the short term as it continues to integrate and grow its existing businesses in order to maximise synergies.

The capital risk management policy remains unchanged from 30 June 2018.

Note 14: Reserves

	Notes	2019 ($)	2018 ($)
Share Based Payments Reserve			
Balance at the beginning of the year		89,486	-
Employee share-based payment expense	17	94,753	89,486
Balance at the End of the Year		184,239	89,486

Share based payments reserve is used to record the value of equity benefits provided to Directors and executives as part of their remuneration.

Note 15: Cash Flow Information

	Notes	2019 ($)	2018 ($)
a. Cash at the end of the financial year as shown in the cash flow statement is reconciled to the related items in the balance sheet as follows:			
Cash at bank		728,315	780,173
Short term deposits		4,000,000	7,000,000
	7	4,728,315	7,780,173
b. Reconciliation of cash flow from operating activities with loss from continuing activities after income tax benefit			
Loss from continuing activities after significant items and income tax		(2,546,159)	(1,753,480)
Non-Cash Items			
Depreciation and amortisation		65,366	31,535
Expense recognised in respect of equity-settled share-based payments		94,753	89,486
Changes In Assets and Liabilities			
(Increase) in trade and other receivables		(762,465)	(30,863)
(Increase) in prepayments		(25,424)	(8,874)
Increase in trade and other payables		164,122	11,527
Increase in provision for employee entitlements		68,211	9,370
Net Cash Used In Operating Activities		(2,941,596)	(1,651,299)

Note 16: Related Party Transactions

Rhythm Biosciences Limited is the parent entity. Refer to Note 3 for details on the subsidiary.

Directors

The names of each person holding the position of director of Rhythm Biosciences Limited during the year were Mr Shane Tanner, Dr Trevor Lockett, Mr David White and Mr Lou Panaccio.

During the 2019 and 2018 financial years there were no transactions with related parties other than remuneration as disclosed in the Remuneration Report.

Note 17: Share-Based Payments

During the financial year the Company granted 504,200 performance rights to Mr Glenn Gilbert as part of his remuneration. These performance rights lapse unless the market capitalisation of the Company at the end of the 12 month period (Relevant Period) after the issue is 20% more than the market capitalisation at the commencement of the Relevant Period. An expense of $8,831 (2018: $nil) is included in key management personnel disclosures (Note 20) and the remuneration report in the directors' report. Details are as follows:

Grant Date	Expiry Date	Vesting Periods	Granted	Exercised	Expired/ Forfeited	Balance at End of the Year	Vested
28.11.2018	27.11.2021	Various	504,200	-	-	504,200	-

For the performance rights granted, the binomial valuation model inputs used to determine the fair value at the grant date, are as follows:

Grant Date	Expiry Date	Vesting Periods	Granted	Exercised	Expired/ Forfeited	Balance at End of the Year	Vested
28.11.2018	27.11.2021	$0.16	Various	75%	-	2.09%	$0.0897

During the 2018 year, 3,000,000 Options were issued to key management personnel at a $nil issue price and a value of $85,922 (2018: $89,486) included in key management personnel disclosures (Note 20) and the remuneration report in the directors' report.

A share option plan has been established by the consolidated entity, whereby the consolidated entity may, at the discretion of the Board, grant options over ordinary shares in the company to certain key management personnel of the consolidated entity. The options are issued for nil consideration and are granted in accordance with performance guidelines established by the Board.

The following Options arrangements existed at 30 June 2019:

Number of Options	Exercise	Vesting Periods	Granted	Exercised	Expired/ Forfeited	Balance at End of the Year	Vested
2,000,000	$0.30	21.7.2017	1 year	21.7.2018	7.12.2020	Dr T Lockett	$0.045
1,000,000	$0.20	21.5.2018	Within 2 years	Various	21.5.2021	G Gilbert	$0.105
3,000,000	**Total ESOP Options**						

Vesting basis: to remain employed by Rhythm at vesting date (ranging from 12 to 24 months).
All options granted are in respect of ordinary shares in Rhythm Biosciences Limited and confer a right of one ordinary share for each option held.

Movement in the number of share options on issue

	2019 Number of Options	2019 Weighted Average Exercise Price (cents)	2018 Number of Options	2018 Weighted Average Exercise Price (cents)
Opening balance	3,000,000	26.67	-	-
Granted	3,000,000	26.67	3,000,000	26.67
Forfeited	-	-	-	-
Exercised	-	-	-	-
Expired	-	-	-	-
Outstanding at Year-end	**3,000,000**	**26.67**	**3,000,000**	**26.67**
Exercisable at year-end	2,500,000	28.00	-	-

The number of options granted during the year pursuant to the ESOP was nil (2018: 3,000,000). The fair value of issued employee share options is calculated to be $nil (2018: $194,100). This amount is expensed over the life of the relevant vesting periods.

Included under employee costs in the income statement is a share-based payments expense of $94,753 (2018: $89,486).

The value of employee share options issued during the financial year has been calculated by using a black-scholes option pricing model applying the following inputs:

	T Lockett	G Gilbert
Options granted	2,000,000	1,000,000
Grant date	21.7.2017	22.5.2018
Exercise price	$0.30	$0.20
Underlying share price	$0.10	$0.175
Expiry date	7.12.2020	21.5.2021
Vesting period	1 year	25% each 6 months over a 2 year period
Expected share price volatility	100%	100%
Risk free interest rate	2.00%	2.21%
Fair value per option at grant date	$0.0445	$0.1051
Total fair value at grant date	$89,000	$105,100

The life of the options is based on the contracted expiry date.

Note 18: Financial Risk Management

The Group's financial instruments consist mainly of term deposits with banks, other receivables and trade payables.

The totals for each category of financial instruments, measured in accordance with AASB 9 as detailed in the accounting policies to these financial statements, are as follows:

	Notes	2019 ($)	2018 ($)
Financial Assets			
Cash and cash equivalents		4,728,315	7,780,173
Trade and other receivables		797,697	35,232
Other financial assets – term deposits		45,000	45,000
		5,571,012	7,861,405
Financial Liabilities			
Trade and other Payables		302,133	138,009
		302,133	138,009

There are no impaired assets within trade and other receivables; these balances, and the balance of trade and other payables, are expected to be settled within 1 year.

Financial Assets Pledged as Collateral

No financial assets have been pledged as security for any financial liability.

Financial Risk Management Policies

The Board are responsible for, among other issues, monitoring and managing financial risk exposures of the Group. The Board monitors the Group's transactions and reviews the effectiveness of controls relating to credit risk, liquidity risk, and market risk. Discussions on monitoring and managing financial risk exposures are held regularly by the Board. The Board's overall risk management strategy seeks to ensure that the Group meets its financial targets, while minimising potential adverse effects of cash flow shortfalls.

The Group did not have any derivative instruments at 30 June 2019.

Specific Financial Risk Exposures and Management

The main risk the Group is exposed to through its financial instruments is liquidity risk.

Credit Risk

Exposure to credit risk relating to financial assets arises from the potential non-performance by counterparties of contract obligations that could lead to a financial loss to the Group.

Credit risk is managed through maintaining procedures ensuring, to the extent possible, that members and counterparties to transactions are of sound credit worthiness.

Credit Risk Exposures

Cash reserves form the majority of the Group's financial assets. At 30 June 2019, cash was deposited with three financial institutions, including two large Australian banks and one foreign exchange market specialist, in order to spread risk and ensure interest rate competitiveness.

Liquidity Risk

Liquidity risk arises from the possibility that the Group might encounter difficulty in settling its debts or otherwise meeting its obligations related to financial liabilities. The Group manages this risk through the following mechanisms:

- preparing forward-looking cash flow analysis in relation to its operational, investing and financing activities; and
- only investing surplus cash with major financial institutions.

Market Risk

Interest Rate Risk

Interest rate risk is the risk that the fair value or future cash flows of a financial instrument will fluctuate as a result of changes in market interest rates. Exposure to interest rate risk arises on interest earned on cash and cash equivalents and term deposits.

The consolidated entity's cash and cash equivalents and term deposits were $4,773,315 as at 30 June 2019 (2018: $7,825,173). An official increase/decrease in interest rates of 100 (2018: 100) basis points would have an adverse/favourable effect on loss before tax of $47,733 (2018: $78,252) per annum. The percentage change is based on the expected volatility of interest rates using market data and analysts forecasts.

Price Risk

Price risk is the risk that the fair value or future cash flows of a financial instrument will fluctuate as a result of changes in market prices. The Group is not exposed to price risk.

Currency Risk

Currency risk is the risk that the fair value or future cash flows of a financial instrument will fluctuate due to changes in foreign exchange rates. The Group's exposure to currency risk is minimal at present as the majority of transactions are in Australian dollars.

Note 19: Segment Reporting

In accordance with Australian Accounting Standard AASB 8 Operating Segments, the Company has determined that it has one reporting segment, consistent with the manner in which the business is managed. This is the manner in which the chief operating decision maker receives information for the purpose of resource allocation and assessment of performance. The Group operates predominantly in one business and geographical segment being the research and development of Biosciences in Victoria, Australia.

Note 20: Key Management Personnel Compensation

The Key Management Personnel compensation included in employee expenses are as follows:

	Share-based payments ($)	Short-term benefits ($)	Post-employment benefit ($)	Other Long-term benefits ($)	Total ($)
2019					
Total compensation	94,753	840,182	52,031	3,745	**990,711**
2018					
Total compensation	89,486	488,370	31,034	-	**608,890**

Further details on the above remuneration is disclosed in the Remuneration Report in the Directors' report.

Note 21: Auditor Remuneration

	2019 ($)	2018 ($)
Remuneration of the Auditor of the Group:		
Auditing or reviewing the financial report	32,278	26,000
Other services:		
- Independent Accountant's Report	-	27,060
- Taxation compliance	20,520	12,650
- Other audit services	-	6,090
	52,798	71,800

Note 22: Events Subsequent to Reporting Date

There has been no matter or circumstance which has arisen since 30 June 2019 that has significantly affected or may significantly affect:

The operations, in financial years subsequent to 30 June 2019, of the consolidated entity; or

The results of those operations, or the state of affairs, in financial years subsequent to 30 June 2019, of the consolidated entity.

Note 23: Commitments

	2019 ($)	2018 ($)
Lease Commitments - Operating		
Within one year	46,118	-
	46,118	-

The above lease relates to the rental of office and laboratory premises at The University of Melbourne, Bio 21 Incubator Building in Parkville, Victoria. The lease expires on 19 March 2020 and has an option for a one year further term.

The Group has no other commitments for expenditure as at 30 June 2019 (2018: $nil).

Note 24: Contingent Assets and Liabilities

The Group has no contingent assets or liabilities as at 30 June 2019 (2018: $nil).

The Directors declare that:

1. The financial statements and notes, as set out on pages 25 to 44 are in accordance with the Corporations Act 2001:
   a. comply with Australian Accounting Standards, the Corporations Regulations 2001 and other mandatory professional reporting requirements; and
   b. give a true and fair view of the Consolidated Entity's financial position as at 30 June 2019 and of its performance for the year ended on that date;
2. The attached financial statements and notes comply with International Financial Reporting Standards as issued by the International Accounting Standards Board as described in note 1 to the financial statements;
3. In the Directors' opinion there are reasonable grounds to believe that the entity will be able to pay its debts as and when they become due and payable; and
4. Remuneration disclosures on pages 17 to 21 comply with section 300A of the Corporations Act 200

This declaration is made in accordance with a resolution of the Directors pursuant to section 295(5)(a) of the Corporations Act 2001.

Shane Tanner
Chairman

Melbourne, Australia
Dated this 29th day of August 2019

Tel: +61 3 9603 1700
Fax: +61 3 9602 3870
www.bdo.com.au

Collins Square, Tower Four
Level 18, 727 Collins Street
Melbourne VIC 3008
GPO Box 5099 Melbourne VIC 3001
Australia

INDEPENDENT AUDITOR'S REPORT

To the members of Rhythm Biosciences Limited

Report on the Audit of the Financial Report

Opinion

We have audited the financial report of Rhythm Biosciences Limited (the Company) and its subsidiaries (the Group), which comprises the consolidated statement of financial position as at 30 June 2019, the consolidated statement of profit or loss and other comprehensive income, the consolidated statement of changes in equity and the consolidated statement of cash flows for the year then ended, and notes to the financial report, including a summary of significant accounting policies and the directors' declaration.

In our opinion the accompanying financial report of the Group, is in accordance with the *Corporations Act 2001*, including:

(i) Giving a true and fair view of the Group's financial position as at 30 June 2019 and of its financial performance for the year ended on that date; and

(ii) Complying with Australian Accounting Standards and the *Corporations Regulations 2001*.

Basis for opinion

We conducted our audit in accordance with Australian Auditing Standards. Our responsibilities under those standards are further described in the *Auditor's responsibilities for the audit of the Financial Report* section of our report. We are independent of the Group in accordance with the *Corporations Act 2001* and the ethical requirements of the Accounting Professional and Ethical Standards Board's APES 110 *Code of Ethics for Professional Accountants* (the Code) that are relevant to our audit of the financial report in Australia. We have also fulfilled our other ethical responsibilities in accordance with the Code.

We confirm that the independence declaration required by the *Corporations Act 2001*, which has been given to the directors of the Company, would be in the same terms if given to the directors as at the time of this auditor's report.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Key audit matters

Key audit matters are those matters that, in our professional judgement, were of most significance in our audit of the financial report of the current period. These matters were addressed in the context of our audit of the financial report as a whole, and in forming our opinion thereon, and we do not provide a separate opinion on these matters.

Carrying Value and Useful Life of Intangible Asset

Key audit matter	*How the matter was addressed in our audit*
Note 9 to the financial report discloses the individual intangible asset, and Note 1 discloses the policy used by the Group for its recognition, measurement and assessment for indicators of impairment. This is a key audit matter due to the materiality of the recorded asset, and the degree of estimation required to be made by the Group, regarding its amortisation period and impairment assessment.	Our procedures included, but were not limited to: • Evaluating whether management's estimate of the amortisation period and amortisation method had changed in the period • Recalculating the amortisation charge for the period. • Evaluating management's assessment of indications of impairment at the reporting date. • Checking the completeness and appropriateness of the disclosures included in the financial report.

Other information

The directors are responsible for the other information. The other information comprises the information in the Group's annual report for the year ended 30 June 2019, but does not include the financial report and the auditor's report thereon.

Our opinion on the financial report does not cover the other information and we do not express any form of assurance conclusion thereon.

In connection with our audit of the financial report, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial report or our knowledge obtained in the audit or otherwise appears to be materially misstated.

If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact. We have nothing to report in this regard.

Responsibilities of the directors for the Financial Report

The directors of the Company are responsible for the preparation of the financial report that gives a true and fair view in accordance with Australian Accounting Standards and the *Corporations Act 2001* and for such internal control as the directors determine is necessary to enable the preparation of the financial report that gives a true and fair view and is free from material misstatement, whether due to fraud or error.

In preparing the financial report, the directors are responsible for assessing the ability of the group to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the directors either intend to liquidate the Group or to cease operations, or has no realistic alternative but to do so.

Auditor's responsibilities for the audit of the Financial Report

Our objectives are to obtain reasonable assurance about whether the financial report as a whole is free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with the Australian Auditing Standards will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of this financial report.

A further description of our responsibilities for the audit of the financial report is located at the Auditing and Assurance Standards Board website (http://www.auasb.gov.au/Home.aspx) at:

http://www.auasb.gov.au/auditors_responsibilities/ar1.pdf

This description forms part of our auditor's report.

Report on the Remuneration Report

Opinion on the Remuneration Report

We have audited the Remuneration Report included in pages 17 to 21 of the directors' report for the year ended 30 June 2019.

In our opinion, the Remuneration Report of Rhythm Biosciences Limited, for the year ended 30 June 2019, complies with section 300A of the *Corporations Act 2001*.

Responsibilities

The directors of the Company are responsible for the preparation and presentation of the Remuneration Report in accordance with section 300A of the *Corporations Act 2001*. Our responsibility is to express an opinion on the Remuneration Report, based on our audit conducted in accordance with Australian Auditing Standards.

BDO East Coast Partnership

James Mooney
Partner

Melbourne, 29 August 2019

Rhythm Biosciences Ltd is quoted on the Australian Securities Exchange (ASX) under the ticker code RHY. The following information was extracted from the Company's records as at 19 August 2019 and is required by the ASX Listing Rules. Rhythm's securities are not quoted on any other stock exchange.

Twenty Largest Holders of Ordinary Shares

Rank	Shareholder	Number of Fully Paid Ordinary Shares	Percentage of Total Issued Capital
1	LOUMEA INVESTMENT PTY LTD	10,000,000	9.93
2	THE TRUST COMPANY (AUSTRALIA) LIMITED	8,038,435	7.98
3	FERNDALE SECURITIES PTY LTD	6,500,000	6.45
4	NORTHERN STAR NOMINEES PTY LTD	4,500,000	4.47
5	COMMONWEALTH SCIENTIFIC & INDUSTRIAL RESEARCH ORGANISATION	2,500,000	2.48
6	KITARA INVESTMENTS PTY LTD	2,400,000	2.38
7	MRS SARAH CAMERON	2,175,000	2.16
8	GIOKIR PTY LTD	2,125,000	2.11
9	NATALIE LOUISE PATTERSON	2,000,000	1.99
10	MOWBRICK PTE LTD	1,650,000	1.64
11	MR DAVID CHARLES NEESHAM & MRS PAMELA CHRISTINE NEESHAM	1,500,000	1.49
12	SHANE FRANCIS TANNER & LISA JANE WHEELER	1,500,000	1.49
13	MR DANIEL EDDINGTON & MRS JULIE EDDINGTON	1,250,000	1.24
14	PERMANENT 4 NOMINEES PTY LTD	1,250,000	1.24
15	SINDEL NOMINEES PTY LTD	1,250,000	1.24
16	ARDROY SECURITIES PTY LTD	1,100,000	1.09
17	MR PETER JAMES NIXON	1,010,000	1.00
18	MR RICHARD STANLEY DE RAVIN	1,000,000	0.99
19	ALITIME NOMINEES PTY LTD	914,802	0.91
20	E & W NOMINEE PTY LTD	866,293	0.86
		55,835,180	55.42
	Balance of register	44,914,820	44.58
	Grand total	100,750,000	100.00

Distribution Schedule

The following is a distribution schedule of the number of holders of fully paid ordinary shares in the Company, within the bands of holding specified by the ASX Listing Rules:

Range	No. of Shareholders	No. of Ordinary Shares	Percentage of Total Issued Capital
100,001 and Over	125	83,460,100	82.84
10,001 to 100,000	361	15,808,567	15.69
5,001 to 10,000	126	1,101,150	1.09
1,001 to 5,000	111	379,503	0.38
1 to 1,000	8	680	0.00
Total	731	100,750,000	100.00

39 shareholders held less than a marketable parcel of fully paid ordinary shares.

Substantial Shareholdings Register

Shareholder	Number of Fully Paid Ordinary Shares	Percentage of Total Issued Capital
Michelle Wing	11,000,000	10.23%
Loumea Investments Pty Ltd	10,000,000	9.93%
Merchant Opportunities Fund	8,160,000	8.10%

A substantial holder is a shareholder who either alone or together with their associates has an interest in 5% or more of the voting shares of the Company.

Options Over Ordinary Shares

Rhythm has options granted under the company's Employee Share Option Plan (ESOP). Each option entitles the holder to purchase one ordinary share in the Company at a predetermined price. No voting rights attach to options. Further details are provided below:

Share Option Type	Number of Options	Number of Holders	Exercise Price (Cents)
Unlisted (ESOP)	2,000,000	1	30
Unlisted (ESOP)	1,000,000	1	20

Escrow Arrangements

38,500,000 shares are subject to mandatory escrow arrangements until 7 December 2019.

Voting Rights

The voting rights attached to ordinary shares are set out below:

Ordinary Shares

On a show of hands every member present at a meeting in person or by proxy shall have one vote and upon a poll each share shall have one vote.

There are no other classes of equity securities.

Directors

Mr Shane Tanner
Dr Trevor Lockett
Mr Louis (Lou) Panaccio
Mr David White

Company Secretaries

Mr Adrien Wing
Ms Pauline Moffatt

Registered and Principal Office

Level 17
500 Collins Street
Melbourne VIC 3000

Auditor

BDO East Coast Partnership
Level 18
727 Collins Street
Melbourne VIC 3000

Legal Advisers

Quinert Rodda and Associates
Suite 1
Level 6
50 Queen Street
Melbourne VIC 3000

Share Registry

Link Market Services Limited
Level 12
250 St Georges Terrace
Perth WA 6000

Phone: +61 1300 554 474

Rhythm Biosciences Limited
ACN 619 459 335

Level 17, 500 Collins Street
Melbourne VIC 3000
Phone +61 3 9614 0600
rhythmbio.com

RHYZ011 08/19